An update from Inspira Technologies Oxy BHN ( (IINN) ) is now available.
On March 14, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced significant advancements in their respiratory care technologies, focusing on the INSPIRA ART500 system designed to replace mechanical ventilators with a safer alternative. The company is concentrating resources on accelerating the INSPIRA ART500’s development and regulatory approval, aiming to capture a substantial share of the $19 billion global mechanical ventilation market. The announcement highlights the company’s strategic milestones, including FDA submissions for new products and expanding deployment in the U.S., which could enhance their market position and stakeholder value.
More about Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd. is a pioneering company in the field of respiratory support and real-time blood-monitoring technologies. The company’s flagship product, the INSPIRA ART500 system, aims to revolutionize critical care by allowing patients to remain awake during treatment while stabilizing oxygen levels without the need for mechanical ventilation. Additionally, the company has developed the FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass procedures and the HYLA blood sensor for continuous, real-time blood monitoring.
YTD Price Performance: -33.33%
Average Trading Volume: 1,235,011
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $19.65M
Find detailed analytics on IINN stock on TipRanks’ Stock Analysis page.